0000000000968440

AUTHOR

R. Pempinello

showing 2 related works from this author

EARLY EFFICACY OF LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF VISCERAL LEISHMANIASIS

1996

The rapidity and efficacy of a short course of liposomal amphotericin B was evaluated in 29 children affected by visceral leishmaniasis (Leishmania infantum). Their overall health status was assessed using the prognostic inflammatory and nutritional index (PINI), and their haematological status by the reticulocyte count and haemoglobin blood levels. All these quantities were measured on day 0, and 3 and 10 d after starting therapy. A significant decrease of inflammatory signs, associated with an improved reticulocyte count, was recorded after 3 d of therapy. A significant increase of haemoglobin levels was also observed 10 d after the start of treatment. The early reduction of inflammatory …

Malemedicine.medical_specialtyAdolescentmedicine.medical_treatmentAntiprotozoal AgentsSeverity of Illness IndexGastroenterologyAmphotericin BAmphotericin BInternal medicineAnimalsHumansMedicineLeishmania infantumChildleishmaniasisDrug CarriersChemotherapybiologybusiness.industryPublic Health Environmental and Occupational HealthInfantAnemiaLeishmaniasisGeneral Medicinebiology.organism_classificationmedicine.diseaseInfectious Diseasesmedicine.anatomical_structureVisceral leishmaniasisItalyChild PreschoolLiposomesImmunologyLeishmaniasis VisceralFemaleParasitologyLiposomal amphotericinHemoglobinBone marrowLeishmania infantumbusinessmedicine.drug
researchProduct

Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).

1996

We evaluated liposomal amphotericin B (AmBisome; Vestar, San Dimas, CA) administered to 88 immunocompetent patients (56 children) with visceral leishmaniasis (VL) caused by Leishmania infantum. Thirteen patients received 4 mg/kg on days 1-5 and 10 (total dose, 24 mg/kg), and all were cured; 42 received 3 mg/kg on days 1-5 and 10 (18 mg/kg), and 41 were cured; 32 received 3 mg/kg on days 1-4 and 10 (15 mg/kg), and 29 were cured (amastigotes were not cleared from 1 child, and 2 relapsed). One adult was cured with a total dose of 12mg/kg. The four children who were not cured received 3 mg/kg for 10 days; none had further relapses. There were no significant adverse events. For VL due to L. infa…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentmedicine.medical_treatmentGastroenterologyDrug Administration ScheduleleishmanisisInternal medicineAmphotericin BAmphotericin BMedicinevisceral leishmaniasisAnimalsHumansLeishmania infantumAdverse effectChildChemotherapyDrug Carriersbiologybusiness.industryInfantLeishmaniasisMiddle Agedmedicine.diseasebiology.organism_classificationSurgeryInfectious DiseasesVisceral leishmaniasisTreatment OutcomeTotal doseChild PreschoolLiposomesLeishmaniasis VisceralLiposomal amphotericinFemaleLeishmania infantumbusinessmedicine.drugClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct